Hiroaki Yokoyama

Hiroaki Yokoyama

Auto-generated profile, based on publicly available information

Hiroaki Yokoyama

Tokushima Red Cross Hospital

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2023 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
TOTomoki Ochiai
Tomoki Ochiai
FYFutoshi Yamanaka
Futoshi Yamanaka
KSKoki Shishido
Koki Shishido
NMNoriaki Moriyama
Noriaki Moriyama
IKIkki Komatsu
Ikki Komatsu
SSShigeru Saito
Shigeru Saito

7 January 2023 in The American Journal of Cardiology
Verified
Journal Article
Open access
HYHiroaki Yokoyama
Hiroaki Yokoyama
YSYoichi Sugiyama
Yoichi Sugiyama
HMHirokazu Miyashita
Hirokazu Miyashita
MJMikko Jalanko
Mikko Jalanko
TOTomoki Ochiai
Tomoki Ochiai
NMNoriaki Moriyama
Noriaki Moriyama
The impact of mild paravalvular regurgitation (PVR) after transcatheter aortic valve implantation (TAVI) remains controversial. We evaluated the impact of mild PVR after TAVI on long-term clinical outcomes. We included patients who underwent TAVI for severe symptomatic aortic stenosis between December 2008 and June 2019 at 2 international centers and compared all-cause death between the group with mild PVR (group 1) and the group with none or trace PVR (group 2). PVR was categorized using a 3-class grading scheme, and patients with PVR ≧ moderate and those who were lost to follow-up were excluded. This retrospective analysis included 1,404 patients (mean age 81.7 ± 6.5 years, 58.0% women). Three hundred fifty eight patients (25.5%) were classified into group 1 and 1,046 patients (74.5%) into group 2. At baseline, group 1 was older and had a lower body mass index, worse co-morbidities, and more severe aortic stenosis. To account for these differences, propensity score matching was performed, resulting in 332 matched pairs. Within these matched groups, during a mean follow-up of 3.2 years, group 1 had a significantly lower survival rate at 5 years (group 1: 62.0% vs group 2: 68.0%, log-rank p = 0.029, hazard ratio: 1.41 [95% confidence interval: 1.04 to 1.91]). In the matched cohort, patients with mild PVR had a significant 1.4-fold increased risk of mortality at 5 years after TAVI compared with those with none or trace PVR. Further studies with more patients are needed to evaluate the impact of longer-term outcomes.

25 March 2024 in Circulation Journal
Verified
Journal Article
Open access
PDF file
YSYoichi Sugiyama
Yoichi Sugiyama
NMNoriaki Moriyama
Noriaki Moriyama
HMHirokazu Miyashita
Hirokazu Miyashita
HYHiroaki Yokoyama
Hiroaki Yokoyama
TOTomoki Ochiai
Tomoki Ochiai
SSShigeru Saito
Shigeru Saito
Background: Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis (AS), but despite estimates of life expectancy after TAVI being essential in heart team discussion, these data are scarce. Therefore, the current study sought to assess long-term survival and its trends in relation to chronological age, surgical risk, and treatment period.Methods and Results: We included 2,414 consecutive patients who underwent TAVI for severe symptomatic AS between 2008 and 2021 at 2 international centers. For the analysis, long-term survival was evaluated according to age, surgical risk, and treatment period categorized into 3 groups, respectively. The longest follow-up was 13.5 years. Overall survival was 67.6% at 5 years and 26.9% at 10 years. Younger patients, lower surgical risk, and later treatment period showed better survival (log-rank P<0.001, respectively). In the multivariate analysis, age <75years, lower surgical risk, and later time period were significantly associated with better survival. The incidence of paravalvular leakage ≥moderate, red blood cell transfusion, and acute kidney injury were independently associated with increasing risk of 5-year death.Conclusions: In a real-world registry, survival was substantial following TAVI, especially in younger and lower surgical-risk patients, with improving outcomes over time. This should be considered in heart team discussions of life-long management for AS patients after TAVI.

25 February 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
KSKoki Shishido
Koki Shishido
NMNoriaki Moriyama
Noriaki Moriyama
THTakahiro Hayashi
Takahiro Hayashi
SYShohei Yokota
Shohei Yokota
HMHirokazu Miyashita
Hirokazu Miyashita
SSShigeru Saito
Shigeru Saito

21 September 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
HYHiroaki Yokoyama
Hiroaki Yokoyama
FYFutoshi Yamanaka
Futoshi Yamanaka
KSKoki Shishido
Koki Shishido
TOTomoki Ochiai
Tomoki Ochiai
SYShohei Yokota
Shohei Yokota
KHKentaro Hayashida
Kentaro Hayashida
Background: Ventricular‐arterial coupling predicts outcomes in patients with heart failure. The arterial elastance to end‐systolic elastance ratio (Ea/Ees) is a noninvasively assessed index that reflects ventricular‐arterial coupling. We aimed to determine the prognostic value of ventricular‐arterial coupling assessed through Ea/Ees after transcatheter aortic valve replacement to predict clinical events. Methods and Results: We retrieved data on 1378 patients (70% women) who underwent transcatheter aortic valve replacement between October 2013 and May 2017 from the OCEAN‐TAVI (Optimized transCathEter vAlvular iNtervention) Japanese multicenter registry. We determined the association between Ea/Ees and the composite end point of hospitalization for heart failure and cardiovascular death by classifying the patients into quartiles based on Ea/Ees values (group 1: 0.666) during the midterm follow‐up after transcatheter aortic valve replacement. During a median follow‐up period of 736 days (interquartile range, 414–956), there were 247 (17.9%) all‐cause deaths, 89 (6.5%) cardiovascular deaths, 130 (9.4%) hospitalizations for heart failure, and 199 (14.4%) composite events of hospitalization for heart failure and cardiovascular death. The incidence of the composite end point was significantly higher in group 2 (hazard ratio [HR], 1.76; 95% CI, 1.08–2.87 [ P =0.024]), group 3 (HR, 2.43; 95% CI, 1.53–3.86 [ P <0.001]), and group 4 (HR, 2.89; 95% CI, 1.83–4.57 [ P <0.001]) than that in group 1. On adjusted multivariable Cox analysis, Ea/Ees was significantly associated with composite events (HR, 1.47 per 1‐unit increase; 95% CI, 1.08–2.01 [ P =0.015]). Conclusions: These findings suggest that a higher Ea/Ees at discharge after transcatheter aortic valve replacement is associated with adverse clinical outcomes during midterm follow‐up. Registration: URL: https://www.upload.umin.ac.jp/ . Unique identifier: UMIN000020423.

1 February 2009 in International Journal of Cardiology
Verified
Journal Article
Closed access
JYJin Yokoyama
Jin Yokoyama
THTakumi Higuma
Takumi Higuma
HTHirofumi Tomita
Hirofumi Tomita
NANaoki Abe
Naoki Abe
KOKoichi Oikawa
Koichi Oikawa
KOKen Okumura
Ken Okumura